KLS-13019
KLS-13019 is a potent, orally bioavailable GPR55 antagonist derived from cannabidiol (CBD) . It demonstrates neuroprotective effects, reversing chemotherapy-induced peripheral neuropathy (CIPN) in vivo and is a research tool for studying hepatic encephalopathy (HE) in preclinical models.
Product Specifications
CAS Number
1801243-39-9
Product Name Alternative
KLS 13019, KLS13019, KLS-13019
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
>99.99% (May vary between batches)
Smiles
C (C) (=C) [C@H]1[C@@H] (C=C (C) CC1) C2=C (O) C=C (CC3CN (C (C) =O) C3) C=C2O
Molecular Formula
C22H29NO3
Molecular Weight
355.47
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
VAng-Cr1452-50gEcoli 50 µg (E. coli)
Recombinant Treponema Pallidum tpn32 Protein (aa 24-268)
Sign In for Pricing
View Details 
IRBAHUEIF2AK4ACAA5C100UL 100 µL
Rabbit Anti Human EIF2AK4 Monoclonal Clone ACAA-5 100UL
Sign In for Pricing
View Details 
bs-8098R-BF350 100 µL
CCDC34 Polyclonal Antibody, AbBy Fluor™ 350 Conjugated
Sign In for Pricing
View Details A0855-70L 50 µg
Activating Transcription Factor 6 (ATF6, ATF6-alpha, ATF6A, Cyclic AMP-dependent Transcription Factor ATF-6 alpha) discontinued
Sign In for Pricing
View Details 
MBS8554317-02 0.1 mL (AF405L)
CCNB3 (Phospho-Ser1063) (Mouse) Rabbit pAb
Sign In for Pricing
View Details